Diagnostic and prognostic value of neutrophil gelatinase-associated lipocalin, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinases-1 for sepsis in the Emergency Department: An observational study

Critical Care

Volumn 18, Issue 6, 2014, Pages

  Wang, Miaomiao ^a   Zhang, Qian ^a   Zhao, Xin ^a   Dong, Guijuan ^a   Li, Chunsheng ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROCALCITONIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN; TIMP1 PROTEIN, HUMAN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSESSMENT; DISEASE SEVERITY; EMERGENCY WARD; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MORTALITY IN EMERGENCY DEPARTMENT SEPSIS SCORE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SEPSIS; SEPTIC SHOCK; SURVIVOR; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; BLOOD; EMERGENCY HEALTH SERVICE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDY; STANDARDS; TRENDS;

ACUTE-PHASE PROTEINS; AGED; BIOMARKERS; EMERGENCY SERVICE, HOSPITAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOCALINS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MORTALITY; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; SEPSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84927721835     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-014-0634-6     Document Type: Article

References (33)

1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41:580-637. 10.1097/CCM.0b013e31827e83af, 23353941.
2. Strehlow MC, Emond SD, Shapiro NI, Pelletier AJ, CamargoJr CA. National study of emergency department visits for sepsis, 1992 to 2001. Ann Emerg Med 2006, 48:326-331. 10.1016/j.annemergmed.2006.05.003, 16934654.
3. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, Barasch J. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2007, 18:407-413. 10.1681/ASN.2006080882, 17229907.
4. Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int 2007, 71:967-970. 10.1038/sj.ki.5002165, 17342180.
5. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 2002, 10:1033-1043. 10.1016/S1097-2765(02)00708-6, 12453412.
6. Hoffmann U, Brueckmann M, Borggrefe M. Matrix metalloproteinases and their inhibitors: promising novel biomarkers in severe sepsis?. J Crit Care 2009, 13:1006. 10.1186/cc8156.
7. Mühl D, Nagy B, Woth G, Falusi B, Bogár L, Weber G, Lantos J. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis. J Crit Care 2011, 26:550-555. 10.1016/j.jcrc.2011.02.011, 21530151.
8. Vanlaere I, Libert C. Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock. Clin Microbiol Rev 2009, 22:224-239. 10.1128/CMR.00047-08, 19366913.
9. Barresi V, Reggiani-Bonetti L, Di Gregorio C, Vitarelli E, Ponz De Leon M, Barresi G. Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) prognostic value in stage I colorectal carcinoma. Pathol Res Pract 2011, 207:479-486. 10.1016/j.prp.2011.05.012, 21726963.
10. Lorente L, Martín MM, Solé-Violán J, Blanquer J, Labarta L, Díaz C, Borreguero-León JM, Orbe J, Rodríguez JA, Jiménez A, Páramo JA. Association of sepsis-related mortality with early increase of TIMP-1/MMP-9 ratio. PLoS One 2014, 9:e94318. 10.1371/journal.pone.0094318, 24727739.
11. Kim H, Hur M, Cruz DN, Moon H-W, Yun Y-M. Plasma neutrophil gelatinase-associated lipocalin as a biomarker for acute kidney injury in critically ill patients with suspected sepsis. Clin Biochem 2013, 46:1414-1418. 10.1016/j.clinbiochem.2013.05.069, 23747960.
12. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. International Sepsis Definitions Conference:SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med 2003, 29:530-538. 10.1007/s00134-003-1662-x, 12664219.
13. Zhang Q, Dong G, Zhao X, Wang M, Li CS. Prognostic significance of hypothalamic-pituitary-adrenal axis hormones in early sepsis: a study performed in the emergency department. Intensive Care Med 2014, 40:1499-1508. 10.1007/s00134-014-3468-4, 25223852.
14. Shapiro NI, Wolfe RE, Moore RB, Smith E, Burdick E, Bates DW. Mortality in emergency department sepsis (MEDS) scores: a prospectively derived and validated clinical prediction rule. Crit Care Med 2003, 31:670-675. 10.1097/01.CCM.0000054867.01688.D1, 12626967.
15. Fliser D, Laville M, Covic A, Fouque D, Vanholder R, Juillard L, Van Biesen W. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant 2012, 27:4263-4272. 10.1093/ndt/gfs375, 23045432.
16. Howell MD, Donnino MW, Talmor D, Clardy P, Ngo L, Shapiro NI. Performance of severity of illness scoring systems in emergency department patients with infection. Acad Emerg Med 2007, 14:709-714. 10.1111/j.1553-2712.2007.tb01866.x, 17576773.
17. Sankoff JD, Goyal M, Gaieski DF, Deitch K, Davis CB, Sabel AL, Haukoos JS. Validation of the Mortality in Emergency Department Sepsis (MEDS) score in patients with the systemic inflammatory response syndrome (SIRS). Crit Care Med 2008, 36:421-426. 10.1097/01.CCM.0B013E3181611F6A0, 18091538.
18. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008, 36:941-952. 10.1097/CCM.0B013E318165BABB, 18431284.
19. Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother 2011, 66:ii33-ii40. 10.1093/jac/dkr121, 21398306.
20. Martensson J, Bell M, Oldner A, Xu S, Venge P, Martling CR. Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury. Intensive Care Med 2010, 36:1333-1340. 10.1007/s00134-010-1887-4, 20397003.
21. Katagiri D, Doi K, Matsubara T. New biomarker panel of plasma neutrophil gelatinase-associated lipocalin and endotoxin activity assay for detecting sepsis in acute kidney injury. J Crit Care 2013, 28:564-570. 10.1016/j.jcrc.2013.01.009, 23499422.
22. Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark Med 2010, 4:265-280. 10.2217/bmm.10.12, 20406069.
23. Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics 1997, 45:17-23. 10.1006/geno.1997.4896, 9339356.
24. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S, Aderem A. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestering iron. Nature 2004, 432:917-921. 10.1038/nature03104, 15531878.
25. Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, Wakeham A, Fong HE, Cheung CC, Mak TW. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coliinfection but not to ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2006, 103:1834-1839. 10.1073/pnas.0510847103, 16446425.
26. Maitra SR, Jacob A, Zhou M, Wang P. Modulation of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in sepsis. Int J Clin Exp Med 2010, 3:180-185. 20827315.
27. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006, 69:562-573. 10.1016/j.cardiores.2005.12.002, 16405877.
28. Maitra SR, Shapiro MJ, Bhaduri S, El-Maghrabi MR. Effect of chemically modified tetracycline on transforming growth factor-beta1 and caspase-3 activation in liver of septic rats. Crit Care Med 2005, 33:1577-1581. 10.1097/01.CCM.0000169880.82060.F7, 16003065.
29. Hoffman U, Bertsch T, Dvortsak E, Liebetrau C, Lang S, Liebe V, Huhle G, Borggrefe M, Brueckmann M. Matrix metalloproteinases and their inhibitors are elevated in sepsis. Prognostic value of TIMP-1 in severe sepsis. Scand J Infect Dis 2006, 38:867-872. 10.1080/00365540600702058.
30. DI Carlo A. Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in sera and urine of patients with kidney tumors. Oncol Lett 2013, 5:1677-1681. 23760084.
31. Lorente L, Martín MM, Labarta L, Díaz C, Solé-Violán J, Blanquer J, Orbe J, Rodríguez JA, Jiménez A, Borreguero-León JM, Belmonte F, Medina JC, Llimińana MC, Ferrer-Agüero JM, Ferreres J, Mora ML, Lubillo S, Sánchez M, Barrios Y, Sierra A, Páramo JA. Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. Crit Care 2009, 13:R158. 10.1186/cc8115, 19799791.
32. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009, 54:1012-1024. 10.1053/j.ajkd.2009.07.020, 19850388.
33. Bagshaw SM, Bennett M, Devarajan P, Bellomo R. Urine biochemistry in septic and non-septic acute kidney injury: a prospective observational study. J Crit Care 2013, 28:371-378. 10.1016/j.jcrc.2012.10.007, 23159144.